

From: [REDACTED]
Cc: [SANTE CONSULT-B5; SANTE PHARMACEUTICALS B5](#)
Subject: FW: Chiesi Farmaceutici - request for a call
Date: jeudi 5 novembre 2020 10:33:33
Attachments: [image001.png](#)
[image002.png](#)
[image003.png](#)
[image008.png](#)
[image009.jpg](#)
[image010.jpg](#)

Dear [REDACTED]

Thank you very much for your email and for the opportunity to have a meeting with Chiesi Farmaceutici.

Unfortunately, due to a very busy period for all colleagues and limited resources we will kindly decline the invitation.

Nonetheless, we would like to stress that the sustainable development and use of pharmaceuticals is one of the key areas of the future pharma strategy and we would be happy to receive from you in writing any ideas or info you may have on this subject.

Kind regards,

Unit “Medicines: policy, authorisation and monitoring”



European Commission

DG Health and Food Safety

This message represents solely the views of its author and can not be regarded as the official position of the Commission. It is intended solely for the person to whom it is addressed and may contain confidential information. If you have received this message in error, please notify me as soon as possible.

From: [REDACTED]
Sent: Friday, October 30, 2020 2:14 PM
To: SANTE CONSULT-B5
Subject: Chiesi Farmaceutici - request for a call

Dear [REDACTED]

I am writing on behalf of Chiesi Farmaceutici to ask for the opportunity of a meeting with you or your Unit.

Chiesi is a European research-focused healthcare group that researches, develops, and markets innovative drugs in the respiratory therapeutics, specialist medicine and rare

disease areas. Chiesi shares authorities' concerns related to the environmental impact of Hydrofluorocarbon (HFC) propellants used in pressurized metered dose inhalers (pMDIs) – hydrofluoroalkanes (HFA) 134a and 227ea. Despite the very limited contribution of HFAs for pharmaceutical use compared to the total F-gases, Chiesi is committed to be the first pharmaceutical company leading the way towards carbon minimal inhaler solutions that preserve patient's health and has recently shared its plans with EMA.

Officially registered as *Benefit Corporation* and being the largest global pharmaceutical group to be awarded B Corp™ Certification, Chiesi strives to minimise the environmental footprint of its products and has planned to become carbon neutral by 2035. As the EU is shifting toward ambitious climate objectives as set in the European Green Deal, Chiesi appreciates DG SANTE's important role in supporting the healthcare sector's transition to greener pharmaceuticals and practices. Chiesi would be grateful for the opportunity of a call with you in the next days to share in more detail its plans and to discuss the sustainable development and use of pharmaceuticals for the future.

We look forward to hearing from you soon.

With kind regards,




Senior Director

FTI Consulting

+ 


23 Avenue Marnix
1000 Brussels Belgium
www.fticonsulting.com
EU Transparency Register: 29896393398-67



"2020 EMEA Public Affairs Consultancy of the Year - Holmes Report"



Learn more about what's happening in Brussels and in the EU on getready4.eu



Confidentiality Notice:

This email and any attachments may be confidential and protected by legal privilege. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the e-mail or any attachment is prohibited. If you have received this email in error, please notify us immediately by replying to the sender and

then delete this copy and the reply from your system. Thank you for your cooperation.

FTI Consulting Belgium SA. A member of FTI Consulting Inc. Registered at Avenue Marnix 23, 1000 Brussels, Belgium. RCB. VAT BE 0478 948 485